Payment overview · 2025
General Payments
$618.05
33 reported records · 9 companies
Healthcare provider profile · identity verified
Kamlesh C Dave, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAGRANGE, KY · NPI 1679599500
Verified facts
What the public records show
CMS Open Payments records show Kamlesh C Dave, MD received $618.05 in general payments during 2025 across 33 reported records.
Vanda Pharmaceuticals Inc. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Qulipta, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $166.25 | 26.9% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $151.54 | 24.5% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.95 | 11.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.72 | 8.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.93 | 8.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.80 | 7.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.49 | 7.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.27 | 3.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.10 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $618.05 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $166.25 | 9 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $166.25 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $151.54 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.95 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $67.95 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.72 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $52.93 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 98 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
109 | 74 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 316 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 304 | 90 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 255 | 36 |
| Omeprazole | Omeprazole | 225 | 71 |
| Azithromycin | Azithromycin | 207 | 120 |
| Montelukast Sodium | Montelukast Sodium | 198 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 49 |
| Gabapentin | Gabapentin | 153 | 23 |
| Metformin Hcl | Metformin Hcl | 152 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 51 |
| Lisinopril | Lisinopril | 150 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 40 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 126 | 126 |
| Meloxicam | Meloxicam | 120 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 113 | 33 |
| Pregabalin | Pregabalin | 113 | 19 |
| Ozempic | Semaglutide | 111 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 109 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 26 |
| Naproxen | Naproxen | 90 | 38 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 88 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 25 |
| Simvastatin | Simvastatin | 86 | 20 |
| Ezetimibe | Ezetimibe | 85 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 25 |
| Sertraline Hcl | Sertraline Hcl | 78 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 20 |
| Trazodone Hcl | Trazodone Hcl | 63 | 20 |
| Furosemide | Furosemide | 62 | 16 |
| Vraylar | Cariprazine Hcl | 62 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 18 |
| Famotidine | Famotidine | 60 | 18 |
| Carvedilol | Carvedilol | 58 | 14 |
| Potassium Chloride | Potassium Chloride | 58 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 17 |
| Januvia | Sitagliptin Phosphate | 53 | 12 |
| Topiramate | Topiramate | 53 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 19 |
| Alendronate Sodium | Alendronate Sodium | 52 | 13 |
| Trulicity | Dulaglutide | 52 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 17 |
| Alprazolam | Alprazolam | 50 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 15 |
| Levofloxacin | Levofloxacin | 49 | 38 |
| Jardiance | Empagliflozin | 47 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 14 |
| Mirtazapine | Mirtazapine | 42 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Cephalexin | Cephalexin | 41 | 35 |
| Fluconazole | Fluconazole | 41 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | 15 |
| Methotrexate | Methotrexate Sodium | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 40 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 40 | 33 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Praluent Pen | Alirocumab | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 11 |
| Sucralfate | Sucralfate | 34 | 18 |
| Baclofen | Baclofen | 33 | suppressed |
| Losartan Potassium | Losartan Potassium | 33 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | 13 |
| Nitroglycerin | Nitroglycerin | 30 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Estradiol | Estradiol | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $618.05 · 33 records | Vanda Pharmaceuticals Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, HETLIOZ, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Qulipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error